Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer

BACKGROUND: Localized rectal cancer responds well to 5-fluorouracil and radiation-based regimens. A phase I–II trial is currently testing the efficacy of adding bevacizumab, a VEGF-specific antibody, to standard chemoradiotherapy. The case presented here is a complete pathological response seen in a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Willett, Christopher G, Duda, Dan G, di Tomaso, Emmanuelle, Boucher, Yves, Czito, Brian G, Vujaskovic, Zeljko, Vlahovic, Gordana, Bendell, Johanna, Cohen, Kenneth S, Hurwitz, Herbert I, Bentley, Rex, Lauwers, Gregory Y, Poleski, Martin, Wong, Terence Z, Paulson, Erik, Ludwig, Kirk A, Jain, Rakesh K
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2007
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2686127/
https://ncbi.nlm.nih.gov/pubmed/17464339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncponc0813
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia